

Radioactive Sources: Applications and Alternative Technologies

Virtual Meeting

Draft Agenda

February 25, 2021 Eastern Time (ET)

Connection Information

Link: <https://nas-sec.webex.com/nas-sec/j.php?MTID=mffd04da528f18c9cbbc2d2bba7ad3db2>

Meeting ID: 199 040 6107

Password: p2P7SMdn9a8 (72777636 from phones and video systems)

Telephone: +1-415-527-5035 US or +1-929-251-9612

Access code: 199 040 6107

11:00 am – 11:02 am	Open PUBLIC SESSION Tom Kroc, Committee Chair
11:02 am – 11:30 am	Remarks from the National Nuclear Security Administration (NNSA) Lance Garrison (NNSA)
11:30 am – 11:50 am	Q+A and Discussion
11:50 am – 12:15 pm	Cobalt-60 Supply Chain and Market Study Jodi Lieberman (Sandia National Laboratories, SNL); Mike Itamura (SNL); Vanessa Vargas (SNL); Joe Adduci (Argonne National Laboratories, ANL); Matthew Keskula (ANL)
12:15 pm – 12:35 pm	Q+A and Discussion
12:35 pm – 12:40 pm	Opportunity for public comments Close PUBLIC SESSION

LIST OF SAMPLE QUESTIONS TO NNSA AND SANDIA

- Please provide an update, if any, on the CIRP program. Have any removals taken place since you last briefed the committee in April 2020? If not, when do you expect those to resume?
- Please provide an update on the cleanup activities at University of Washington following the radiation incident during the recovery of the cesium irradiator.
- Please provide an overview of the SBIR project selection and review process.
 - What are your views on existing support for a SBIR and STTR project to progress from conception of a tech idea to commercialization.
 - Are you coordinating with any of the applied programs within DOE to further develop a technology from TRL4 and above and if yes, what programs and how do you achieve that? Please provide an example of a success story, if applicable.
- Please explain your role as *promoter* of alternative technologies.
 - Are you promoting the concept of the alternative technologies or the alternative technologies themselves? If the latter, what technologies do you promote for each of the applications the committee has been asked to examine?
 - Do you see your role limited to promoting radiation-emitting modalities or are you also promoting non-radiation alternatives (for example genetic modification for SIT; EtO for industrial sterilization). If you also promote non-radiation alternatives, how do you engage with the experts from those communities?
- Related to the above, the committee would like to understand how this promoting role fits within the statutory definition of the agency's purpose as enacted by Congress. It would help for example, if you could describe the history of adding the "promoting alternative technology" in your mission.
- Please discuss, if possible, current work on cost-benefit analysis for adopting alternatives in industrial sterilization applications. What is the process for the analysis and what is the timeline?